Sun, "Concurrent chemoradiotherapy
plus adjuvant chemotherapy versus concurrent chemoradiotherapy
alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial," The Lancet Oncology, vol.
As a chemo- and radiosensitive tumor, the current standard treatment for locally advanced NPC is concurrent chemoradiotherapy
[4,5], which can result in 5-year survival and disease-free rates up to 70% [6,7].
(CCRT) improves overall survival (OS), disease-free survival (DFS) and local regional control and has become the standard treatment for squamous cell carcinoma in head and neck (SCCHN).
Besides the expected synergistic effects of the two different treatment modalities (TMZ and radiotherapy), a possible disadvantage of concurrent chemoradiotherapy
is that it bears the risk of increased toxicity and side effects.
was performed with radiotherapy 70.2 Gy and chemotherapy of CDDP and VP16 for 4 times under the consideration of unresectable neck metastases.
However, there are the risks of recurrence because of remaining micrometastases after RHy, and adjuvant radiotherapy or concurrent chemoradiotherapy
(CCRT) are needed to improve survival.
Therefore, recent studies have focused on the use of concurrent chemoradiotherapy
(CCRT) to achieve results with respect to disease control and survival, as well as to preserve organ function so that patients can speak and eat as normally as possible.
Recently, a new study has reported that neoadjuvant chemotherapy followed by radical hysterectomy (NAC+RH) improves survival of patients with locally advanced cervical cancer in comparison to concurrent chemoradiotherapy
Most cases were treated by concurrent chemoradiotherapy
(66%) followed by adjuvant chemotherapy.
The standard therapy is IAIC followed by surgical intervention and postoperative concurrent chemoradiotherapy
. Therefore, this retrospective study investigated how the IAIC-surgery interval affects outcomes of treatment for locally advanced OSCC.